Vericel Co. (NASDAQ:VCEL) Shares Bought by Congress Wealth Management LLC DE

Congress Wealth Management LLC DE raised its position in Vericel Co. (NASDAQ:VCEL) by 4.4% in the 4th quarter, Holdings Channel reports. The fund owned 182,273 shares of the biotechnology company’s stock after acquiring an additional 7,664 shares during the period. Congress Wealth Management LLC DE’s holdings in Vericel were worth $10,009,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also made changes to their positions in the company. Arcadia Investment Management Corp MI acquired a new stake in Vericel in the fourth quarter valued at about $48,000. Smartleaf Asset Management LLC raised its stake in shares of Vericel by 511.1% during the 4th quarter. Smartleaf Asset Management LLC now owns 1,265 shares of the biotechnology company’s stock worth $70,000 after buying an additional 1,058 shares in the last quarter. Geneos Wealth Management Inc. lifted its holdings in shares of Vericel by 826.6% in the 4th quarter. Geneos Wealth Management Inc. now owns 2,511 shares of the biotechnology company’s stock valued at $138,000 after buying an additional 2,240 shares during the period. Quantbot Technologies LP purchased a new stake in shares of Vericel in the third quarter valued at approximately $146,000. Finally, KBC Group NV grew its holdings in Vericel by 82.5% during the fourth quarter. KBC Group NV now owns 2,707 shares of the biotechnology company’s stock worth $149,000 after acquiring an additional 1,224 shares during the period.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on the stock. HC Wainwright restated a “buy” rating and set a $60.00 target price on shares of Vericel in a research report on Friday, February 28th. BTIG Research boosted their price objective on shares of Vericel from $56.00 to $66.00 and gave the stock a “buy” rating in a report on Tuesday, November 26th. Truist Financial reaffirmed a “buy” rating and issued a $61.00 target price (down from $67.00) on shares of Vericel in a report on Monday, March 3rd. Stephens reissued an “overweight” rating and set a $65.00 price target on shares of Vericel in a research note on Wednesday, January 15th. Finally, Canaccord Genuity Group upped their price target on Vericel from $64.00 to $67.00 and gave the stock a “buy” rating in a report on Monday, February 3rd. One research analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $62.29.

Insider Activity at Vericel

In other Vericel news, Director Robert L. Md Zerbe sold 2,500 shares of Vericel stock in a transaction that occurred on Wednesday, February 5th. The shares were sold at an average price of $62.50, for a total value of $156,250.00. Following the completion of the sale, the director now directly owns 26,595 shares of the company’s stock, valued at approximately $1,662,187.50. The trade was a 8.59 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Dominick Colangelo sold 26,592 shares of the stock in a transaction on Thursday, March 13th. The stock was sold at an average price of $45.78, for a total value of $1,217,381.76. Following the transaction, the chief executive officer now directly owns 259,997 shares in the company, valued at approximately $11,902,662.66. This represents a 9.28 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 34,092 shares of company stock valued at $1,683,582. 5.20% of the stock is owned by corporate insiders.

Vericel Price Performance

VCEL stock opened at $47.94 on Tuesday. The company’s 50 day simple moving average is $54.16 and its 200-day simple moving average is $51.73. Vericel Co. has a 12 month low of $39.12 and a 12 month high of $63.00. The firm has a market capitalization of $2.40 billion, a PE ratio of 799.13 and a beta of 1.78.

Vericel Company Profile

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.